HedgePath Pharmaceuticals Announces Completion of $5.5 Million Private Placement Offering

Funds raised will support ongoing Phase II(b) clinical trial in Basal Cell Carcinoma Nevus Syndrome, an orphan cancer hereditary disease requiring life-long therapy with no approved pharmaceutical treatment License and Manufacturing Partner Mayne Pharma invests $2.8MM PR Newswire TAMPA, Fla. and SAN DIEGO, June 1, 2016 TAMPA, Fla. and SAN DIEGO, June 1, 2016 /PRNewswire/ HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced The post HedgePath Pharmaceuticals Announces Completion of $5.5 Million Private Placement Offering appeared first on Public Wire.
http://bit.ly/1TQbZ1S

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: